Modality
mAb
MOA
WEE1i
Target
KRASG12D
Pathway
Ferroptosis
RettALL
Development Pipeline
Preclinical
~Jan 2023
→ ~Apr 2024
Phase 1
Jul 2024
→ Jul 2031
Phase 1Current
NCT06777860
1,685 pts·Rett
2024-07→2031-07·Not yet recruiting
1,685 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-275.3y awayPh2 Data· Rett
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Not yet…
Catalysts
Ph2 Data
2031-07-27 · 5.3y away
Rett
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06777860 | Phase 1/2 | Rett | Not yet recr... | 1685 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |